INTRODUCTION
============

Bisphosphonates (BPs) are widely used medications mainly for the treatment and management of skeletal and oncological diseases such as breast, lung and prostate cancers, multiple myeloma, hypercalcemia, osteoporosis and Paget's disease. According to IMS Health \[[@B1]\], in 2006 around 190 million units of intraoral BPs (mostly used for treatment osteoporosis and osteopenia) were utilized world-wide not to mention usage of intravenous BPs (to treat malignant skeletal oncological diseases) thus referring to Wysowski et al. \[[@B2]\] Approximately 14,7 million intraoral BP prescriptions were dispensed in the US alone in 2012. Although, BPs greatly increase the quality of life for patients, there is a chance that BP-related osteonecrosis (BRONJ) of the jaw may occur ([Table 1](#T1){ref-type="table"}). Risk factors enhancing BRONJ are periodontal surgery, implant placement, tooth extractions, poor condition of dental prosthesis or chronic mechanical trauma of the jaw bone. Moreover, systemic diseases, consumption of other medications, smoking and alcohol consumption have had a great influence on BP-related osteonecrosis. The occasions of BRONJ have demographic correlations as well for the Caucasian race \[[@B3]\]. Most of the patients treated with bisphosphonates, due to their age, have partial or full edentulism, the need for functional and aesthetic oral rehabilitation by means of dental implantation, which is common in this group of patients \[[@B4]\]. Therefore, the aim of this article is to investigate studies targeted at bisphosphonates effects on dental implant placement procedure.

###### 

Staging and treatment of BRONJ according to reviewed studies^a^

  ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Risk category**   No clinical/radiological evidence of exposed bone or infection/inflammation.
                      
  Treatment plan      No surgical treatment is needed. Patient has to be informed about following risks. Good oral hygiene with re-examinations at least once every 6 months should be done.
                      
  **Stage I**         Clinical evidence of exposed bone for more than 8 weeks. This stage is usually asymptomatic. No signs infection is normally seen.
                      
  Treatment plan      No surgical treatment is needed. Antibacterial mouth rinses, professional oral hygiene with no injury of exposed bone can be considered, common follow-ups for exposed bone re-evaluation. Antibiotic treatment can be prescribed if patients condition is difficult.
                      
  **Stage II**        Exposed/ necrotic bone with signs of infection, drainage of inflammatory matter can appear.
                      
  Treatment plan      Management of pain, broad-spectrum antibiotics, antibacterial mouthrinses, debridement of necrotic bone surface area, common follow-ups with professional oral hygiene and re-evaluation of necrotic bone. Drug holidays may be considered as an option.
                      
  **Stage III**       Exposed/ necrotic bone with sings of infection. Extraoral fistula, pathological fractures can appear.
                      
  Treatment plan      Antibacterial mouthrinses and broad spectrum antibiotics with pain management to prepare patient for surgical intervention-resection of necrotic bone. Drug holidays may be considered as an option.
  ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Stages applies for patients, who used or are using intraoral/intravenous bisphosphonates, and had no history of radiotherapy of head/neck.

MATERIAL AND METHODS
====================

**Protocol and registration**

Methodology of this article was documented and registered in advance. "Prospero" register no.: CRD42018082609. Protocol can be assessed at: <https://www.crd.york.ac.uk/prospero/>

The reporting of this systematic analysis adhered to the PRISMA (Preferred Reporting Item for Systematic Review and Meta-Analyses) Statement \[[@B5]\].

**Focus question**

The focus question was developed according to the population, intervention, comparison, and outcome (PICO) design ([Table 2](#T2){ref-type="table"}).

###### 

The focus question development according to the PICOS study design

  ---------------------- ------------------------------------------------------------------------------------
  Component              Description
                         
  **Problem (P)**        Osteonecrosis of the jaw.
                         
  **Intervention (I)**   Dental implant placement on patients with bisphosphonate therapy.
                         
  **Comparison (C)**     Comparison between patients with intraoral and intravenous bisphosphonate therapy.
                         
  **Outcome (O)**        Bisphosphonate related osteonecrosis of the jaw.
                         
  **Study design (S)**   Randomized controlled trial.
                         
  **Focus question**     Is dental implant placement purposeful for patients using bisphosphonates?
  ---------------------- ------------------------------------------------------------------------------------

**Types of publications**

The review included studies, case reports, clinical trials on human subjects that were published in English between 2006 and 2017. Letters, editorials, literature reviews, PhD theses, and abstracts were excluded.

**Types of studies**

The review included *in vivo* (human trials), prospective and retrospective studies published from May 1st, 2006, to December 1st, 2017, that reported on patient's oral rehabilitation with dental implants using BP medication.

**Information sources**

A search was conducted on the "MEDLINE, PubMed, PubMed Central and ResearchGate databases.

**Literature search strategy**

According to the PRISMA guidelines, an electronic search was conducted using the MEDLINE, PubMed, PubMed Central and ResearchGate databases to locate articles concerning implant placement in patients using BPs. The keywords that were used during the primary stage were as follows: (((Bisphosphonates) OR BP related osteonecrosis of the jaw) OR (BP osteonecrosis) OR dental implant).

**Selection of studies**

The resulting articles were independently subjected to clear inclusion and exclusion criteria by two reviewers as follows. The reviewers compared decisions and resolved differences through discussion, consulting a third party when consensus could not be reached. The third party was an experienced senior reviewer. Full reports were studied of the articles that were deemed eligible for inclusion in this paper ([Figure 1](#fig1){ref-type="fig"}).

![Flow diagram of studies selection according PRISMA guidelines.](jomr-09-e2-g001){#fig1}

**Population**

Patients presented in the included studies must have been currently using or had used BPs in relation to oral rehabilitation with screw-shaped dental implants with at least a 1-year follow-up after a surgical implant placement operation.

**Inclusion criteria**

The applied inclusion criteria for the studies were as follows:

-   Studies written in English.

-   Patient had to be treated with at least one dental implant before or during oral or intravenous BP therapy.

-   Clinical reports with at least a 12-month follow-up.

-   Studies regarding information on BP therapy complications (osteonecrosis of the jaw) and dental implant treatment outcome (survival rate).

**Exclusion criteria**

Exclusion criteria for study selection were as follows:

-   Previous radiotherapy of head and/or neck area had been done.

-   Malignant pathologies or active inflammations were examined at time of implantation.

-   Studies of adolescents (under 18 years of age) and elderly people (older than 80).

-   *In vitro* and animal studies.

-   Systematic reviews.

**Sequential search strategy**

Following the initial literature search, all articles were screened and excluded based on titles and abstracts. The final stage of screening involved reading the full texts to confirm each study's eligibility, based on the inclusion and exclusion criteria.

**Data extraction**

The data were independently extracted from studies in the form of variables, according to the aims and themes of the present review, as listed onwards.

**Data items**

Data were collected from the included articles and arranged in the following fields:

-   "Type of drug" - intraoral or intravenous BP medication.

-   "Reason of medication" - motive why BPs are used.

-   "Mean age of medication use" - medium time interval of medication used among the patients.

-   "Implants in control group" - number of implants placed in patients with no history of BP therapy.

-   "Implants in study group" - number of implants placed in patients during or after BP therapy.

-   "Implant survival rate in control group" - success rate of implants during follow-ups among the patients without a history of BP therapy.

-   "Implant survival rate in study group" - success rate of implants during follow-ups among the patients on BP therapy.

-   "Mean age of follow-up" - medium time interval of follow-ups for patients after implant placement.

-   "Year" - reveals the year of publication.

**Assessment of methodological quality**

The quality of all included studies was assessed during the data extraction process. The Cochrane Collaboration's two-part tool for assessing risk of bias \[[@B6]\] was used to assess bias across the studies and identify papers with intrinsic methodological and design flaws ([Table 3](#T3){ref-type="table"}). The Cochrane risk of bias tool was used for randomized clinical trial assessment, and appraisal checklist tool \[[@B7]\] was used for case reports ([Table 4](#T4){ref-type="table"}). Nonrandomized studies were not found during the literature search.

###### 

Quality assessment for randomized clinical trials (Cochrane risk of bias tool) \[6\]

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                      Year of\      Random sequence generation   Allocation concealment   Blinding of\                 Blinding of\         Incomplete outcome data   Selective reporting   Other bias
                             publication                                                         participants and personnel   outcome assessment                                                   
  -------------------------- ------------- ---------------------------- ------------------------ ---------------------------- -------------------- ------------------------- --------------------- ------------
  Siebert et al. \[33\]      2015          High                         High                     Low                          High                 Low                       Low                   Low

                                                                                                                                                                                                   

  Lazarovici et al. \[34\]   2010          High                         High                     Unclear                      High                 Low                       Low                   Low

                                                                                                                                                                                                   

  Shabestari et al. \[36\]   2010          High                         High                     Unclear                      High                 Low                       Low                   High

                                                                                                                                                                                                   

  Bell and Bell \[37\]       2008          High                         High                     Unclear                      High                 Low                       Low                   Low

                                                                                                                                                                                                   

  Fugazzotto et al. \[38\]   2007          High                         High                     Unclear                      High                 Low                       Low                   High

                                                                                                                                                                                                   

  Jeffcoat \[39\]            2006          High                         Low                      Low                          High                 Low                       Low                   Low
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Quality assessment for case reports (the Joanna Briggs Institute appraisal checklist tool) \[7\]

  --------------------------------------------------------------------------------------------------------------------------
  Appraisal checklist                                                                    Study                  
  -------------------------------------------------------------------------------------- ------------ --------- ------------
  Were patient\'s demographic characteristics clearly described?                         Yes          Yes       Yes

                                                                                                                

  Was the patient\'s history clearly described and presented as a timeline?              Yes          Yes       Yes

                                                                                                                

  Was the current clinical condition of the patient on presentation clearly described?   Yes          Yes       Yes

                                                                                                                

  Were diagnostic tests or assessment methods and the results clearly described?         Yes          Yes       Yes

                                                                                                                

  Was the intervention(s) or treatment procedure(s) clearly described?                   Yes          Yes       Yes

                                                                                                                

  Was the post-intervention clinical condition clearly described?                        Yes          Yes       Yes

                                                                                                                

  Were adverse events (harms) or unanticipated events identified and described?          Not\         Yes       Not\
                                                                                         applicable             applicable

                                                                                                                

  Does the case report provide takeaway lessons?                                         Yes          Yes       Yes

                                                                                                                

  Overall appraisal: \[Yes/No/Unclear/Not applicable\]                                   Include      Include   Include
  --------------------------------------------------------------------------------------------------------------------------

**Synthesis of results**

Relevant data of interest on the previously stated variables were collected and organized into [Table 5](#T5){ref-type="table"}.

###### 

Implant survival rate among the studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Type of drug                  Reason of medication                        Mean age of\      Implants in control group   Implants in study group   Implant survival rate\   Implant survival rate\   Mean age of follow-up\
                                                                                                          medication use\                                                         in control group         in study group           (months)
                                                                                                          (months)                                                                                                                  
  ----------------------------- ----------------------------- ------------------------------------------- ----------------- --------------------------- ------------------------- ------------------------ ------------------------ ------------------------
  Rugani et al. \[31\]          Iv BP\                        Osteoporosis                                12                \-                          2                         \-                       100%                     16
                                (ibandronate)                                                                                                                                                                                       

                                                                                                                                                                                                                                    

  Sverzut et al. \[32\]         Iv BP (zoledronic acid)       Breast cancer                               72                \-                          3 + 3                     \-                       0%                       18 + 6

                                                                                                                                                                                                                                    

  Siebert et al. \[33\]         Iv BP (zoledronic acid)       Osteoporosis                                30                60                          60                        100%                     100%                     12

                                                                                                                                                                                                                                    

  Lazarovici^a^ et al. \[34\]   Oral BP (alendronate)         Osteoporosis\                               68                \-                          11 patients               \-                       7 patients\              11.4
                                                              breast, prostate cancer, multiple myeloma                                                                                                    (63%)                    

                                                                                                                                                                                                                                    

  Iv BP (zoledronic acid/\      68                            16\                                         5 patients\                                                                                                               
  pamidronate)                                                patients                                    (31%)                                                                                                                     

                                                                                                                                                                                                                                    

  Torres et al. \[35\]          Oral BP\                      Paget\'s disease                            84                \-                          6                         \-                       100%                     48
                                (Risedronate)                                                                                                                                                                                       

                                                                                                                                                                                                                                    

  Shabestari et al. \[36\]      Oral BP (alendronate)         Osteoporosis                                20.5              \-                          46                        \-                       100%                     51.6

                                                                                                                                                                                                                                    

  Bell and Bell \[37\]          Oral BP\                      Osteoporosis                                From 6 to 132     734                         100                       96.5%                    95%                      37.2
                                (alendronate/ risedronate/\                                                                                                                                                                         
                                ibandronate)                                                                                                                                                                                        

                                                                                                                                                                                                                                    

  Fugazzotto et al. \[38\]      Oral BP\                      Osteoporosis                                39.6              \-                          169                       \-                       100%                     18.2
                                (alendronate/\                                                                                                                                                                                      
                                risedronate)                                                                                                                                                                                        

                                                                                                                                                                                                                                    

  Jeffcoat \[39\]               Oral BP\                      Osteoporosis                                36                108                         102                       99.2%                    100%                     36
                                (alendronate/\                                                                                                                                                                                      
                                risendronate)                                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Lazarovici et al. \[34\] case concluded patients that already showed with implant-related BRONJ. Antibiotic therapy and canceling BP medication was the treatment strategy. And implant survival rate after the treatment was 63% (Intraorally medicated patients) and 31% (intravenously medicated patients).

Iv = intravenous; BP = bisphosphonates.

**Statistical analysis**

No meta-analysis could be performed due to the heterogeneity between the studies.

RESULTS
=======

**Study selection**

Article review and data extraction were performed according to the PRISMA flow diagram. The initial search identified a total of 297 articles ([Figure 1](#fig1){ref-type="fig"}). The inclusion and exclusion criteria were applied to the 32 full-text articles. Finally, 9 articles were included in the review.

**Exclusion of studies**

The reasons for excluding studies after full-text assessment were as follows: non-human studies (n = 5) \[[@B8]\], *in vitro* studies (n = 2) \[[@B13]\], systematic reviews (n = 16) \[[@B15]\].

**Risk of bias across studies**

Summarizing the risk of bias for each randomized clinical trial, no studies were classified as an unclear or low risk (of bias for one or more key domains); due to similar methodologies of the studies, all of them appeared to have a high risk (of bias for more than one domain) \[[@B31]\]. Siebert et al. \[[@B33]\] and Jeffcoat \[[@B39]\] presented most of the low-risk domains corresponding with 4 and 5 out of the 7 fields ([Table 3](#T3){ref-type="table"}). All the recapped case reports showed high appraisal with only 1 field (Were adverse events \[harms\] or unanticipated events identified and described?) in both Rugani et al. \[[@B31]\] and Torres et al. \[[@B35]\] appearing to be "Not applicable" ([Table 4](#T4){ref-type="table"}).

**Study characteristics**

Results were summed up ([Table 5](#T5){ref-type="table"}) using an evaluation of drug type, time interval of BP use, number of implants placed in study group with their success rate, success rate of implants placed in control group and interval of re-examinations.

**Intravenous medication outcomes**

Rugani et al. \[[@B31]\] published a successful case report in 2015. A patient with osteoporosis was treated with intravenous BPs for more than a year. Over the time, BRONJ was diagnosed, so the medication was suspended. Local inflammation treatment, removal of necrotic parts, surgical revision of the wound and wound closure was used to stop the inflammation. A 9-month follow-up confirmed better condition of soft tissue and regeneration of necrotic bone. After confirmation that no pathological or inflammatory elements occurred in the jaw, an implantation procedure was planned. Two implants were inserted in the first and second mandibular left molar space. The standard protocol for implantation was used, and no complications were observed at the healing stage. Sixteen months later no inflammatory signs in soft and bone tissues were observed. In 2012, Sverzut et al. \[[@B32]\] in a case report presented a female patient with a history of breast cancer treatment; radiotherapy and chemotherapy were finished in 1995. From 2003 to 2009, the patient had to receive an intravenous infusion of BP therapy once a month. In 2004, she had an implantation procedure in the right posterior region of her mandible and due to the pathological mobility, all the implants had to be removed (3 implants were placed that time) after 1.5 years of prosthetic treatment on implants. Later on in 2008, the same oral surgeon performed an implantation procedure for the same patient in the left posterior region of the mandible. Three implants were inserted and 6 months later, the patient was addressed to her physician at the oral and maxillofacial surgery clinic to confirm implant-related BRONJ. Another study was published by Siebert et al. \[33\] in 2015. Twenty four female patients were divided into 2 groups. Group A consisted of 12 participants receiving intravenous BPs from osteoporosis ranging from 2 to 3 years of medication usage; group B was a control group without osteoporosis or any medication usage. Both groups of partially edentulous patients had their poor-condition teeth removed, and implants were immediately inserted. All the patients received antibiotic therapy (Amoxiclave: 1g. twice a day) during the post-operative stage for 6 days. After the 1-year follow-up, the survival rate of implants was 100% for both groups.

Lazarovici et al. \[[@B34]\] published a case in 2010 with examination of 145 patients of whom 27 had implant-related osteonecrosis of the jaw. Eleven patients used oral BPs, and the rest had their medication infused intravenously. Mean length of medication usage time before appearance of BRONJ symptoms was 68 months. All the participants with implant-related osteonecrosis had to start antibiotic therapy, and if no sign of improvement was seen after the long-term therapy, the implant had to be removed. Overall, 16 patients had their inflammated bone implants removed and continued the antibiotic treatment (doxicicline: 100 - 200 mg/day) until the full recovery was seen. Implant removal was not necessary for the rest of the patients because significant recovery was seen in the malignant area. Clinical observations after treatment expanded from 3 to 43 months.

**Intraoral medication outcomes**

Torres et al. \[[@B35]\] published the clinical case in 2009. In 2003, a 64-year-old woman with long-term oral BP medication from polyostotic Paget's disease was examined for mouth rehabilitation treatment. Intraoral BPs had been used weekly since 1996. The treatment plan was to do implant-supported fixed prosthesis in the posterior partially edentulous maxilla. Six implants were placed in the right and left posterior regions following a routine protocol. A 10-day antibiotic therapy was prescribed (amoxicillin: three 750-mg tabs/day). No post-operative pathological soft tissue or bony lesions were seen, and 6 months after implant placement, they were loaded with bridges. The patient was followed-up for 4 years, and the implants were successfully functional, and no peri-implant inflammation or implant mobility was seen.

Another publication written by Shabestari et al. \[[@B36]\] in 2010 involved a 21-patient study. All patients were osteoporotic women of whom 14 started BP therapy after implantation and tissue healing, and 7 of them already used intraoral BPs before implantation. Every patient had additional supplementary vitamin D and Calcium. All implants had been placed using a trans-gingival unloaded healing protocol. No significant difference was seen between post- or pre-use of the oral BPs or type of prosthesis, and none of the participants suffered from implant-related BRONJ post-insertion of implants during 0- to 36-month follow-ups.

A retrospective study in 2008 was published by Bell and Bell \[[@B37]\] and involved examination of 100 dental implants in 42 patients. Intraoral BPs were prescribed from 6 months to 11 years and were still successfully being used after the surgery. Thirty participants of the group also received not only dental implants but also bone grafts, including 41 socket grafts, 10 sinus lifts, 13 guided tissue regenerations, 1 tunnel graft and 3 buccal contour regenerations. The mean duration of follow-up was 3.1 years (the shortest was 3 months, and the longest was 7.5 years) to ensure that no bone loss or inflammation occurred. Five implants failed, resulting in a 95% success rate (96.5% success rate in 734 implants inserted by the same operator in the same year in patients without any history of BPs); although, oral BPs did not seem to be the reason for implant failure.

Fugazzotto et al. \[[@B38]\] presented a case of 61 patients, published in 2007. Participants of the case had a history of oral BP usage with a mean age of 3.3 years (interval from 1 to 5 years). One hundred sixty nine implants were placed, including 43 implants placed at the time of tooth removal. Range of follow-ups were from 12 to 18 months and from 19 to 24 months respectively for 96 and 73 patients. All the participants showed no exposure of the bone or processes of inflammation that could confirm BRONJ, excluding 1 patient who was 1-week post-operation and showed 2 - 3 mm exposed bone near the implant; although, the tissues were minimally debrided with a success of newly granulated soft tissue covering the exposed area.

Jeffcoat \[[@B39]\] published a controlled study on the alveolar bone taking effect from oral BPs in 2006. Twenty five postmenopausal women were using intraoral drugs for the mean age of 3 years. The control group of 25 age-matching participants were chosen with no history of BP therapy. One hundred two implants were placed in the BP-using participants versus 108 implants place in the control group subjects. Three years of examinations (radiographical and clinical diagnostics) with at least 1 visitation once a year showed a 100% success rate in the medicated group and a 99.2% success rate in the control group, resulting in no significant difference between groups.

Overall, implant failure was considered if:

-   Implant mobility appeared.

-   Active inflammation for more than 8 weeks without healing with antibiotic therapy.

-   Any sign of necrotic bone or unhealed soft tissues.

-   Drainage of inflammatory matter near implant.

-   Appearance of implant-related osteonecrosis of the jaw during follow-up.

**Outcome measures**

In conclusion, with outcomes put in ([Table 5](#T5){ref-type="table"}), only 14 patients were treated with intravenous medication and had 68 implants inserted. The interval of treatment by BPs was from 1 to 6 years. The average success rate of implant survival was 91% with 6 implants removed for one patient, who had 6 years of medication infusions intravenously, considering that other patients who showed success in implant stability were only medicated with intervals from 12 months to 2,5 years. Meanwhile, the control group was only studied in one research case with 12 patients and showed a 100% implant survival rate.

Patients with intraoral usage of medication showed better results with a sum of 150 patients who had 423 implants placed. The interval of intraoral medication use was from 6 months to 11 years. Showing no significant difference in the implant survival rate, which was 98.8% with only 5 implants out of 423 failed. The control groups from the 2 articles showed 97% success rate with only 27 implants failed out of 842. This gives us a better percentage of implant healing with intraoral BPs than with no medication usage in the control group and in the intravenously treated group, which was unreliable (considering that number of patients treated intravenously was too small). Lazarovici et al. \[[@B34]\] published a case series that was excluded out of the total results because the examined patients already had implant-related BRONJ. Eleven patients used oral and 16 used intravenous BPs. Patients had to start long-term antibiotic therapy until full recovery and stabilization of the implants; if no difference was seen, the implants had to be removed. For 7 (63%) patients using intraoral BPs, full recovery was seen without need to remove dental implants, and for intravenously treated patients, only 5 (31%) recovered.

DISCUSSION
==========

BPs have been commonly used for more than two decades. This type of medication helps millions of postmenopausal women stabilize the processes of osteoporosis; they are drugs of choice for malignant skeletal diseases to decrease resorption and pathological fractures of bone, and they benefit patients with hypercalcemia and Paget's disease. Although, some manipulations in the maxilla or mandible such as teeth extractions, periodontal surgeries, implantation procedures or other surgically invasive oral procedures on BPs was highly discussed and discouraged in lots of literature sources because of possible BRONJ occurrence. It is difficult to manage this type of osteonecrosis even though there have been numerous successful cases, treatment protocols and strategies presented in the time range from the first BRONJ that was published by Marx \[[@B40]\] in 2003. The basis of BP-induced osteonecrosis staging has not changed in the time ([Table 1](#T1){ref-type="table"}), although moderations of treatment were found and tested. With advanced healing strategies and experience with BPs, there is a possibility to increase the patient's quality of life fully, meaning that full or partial mouth rehabilitation may be considered with dental implant placement. Reviews of case studies have shown that with the right planning (radiographic evaluations, reduction of unhealthy habits), examination of patients (type of disease, time of medication use, type of BPs, anamnesis) and good inspection of clinical evidence (oral hygiene, removal of improper prosthesis or dental restorations), it is possible to use dental implants even in patients on BP therapy. Although, risk factors should be evaluated because for patients with intravenous infusions of BPs, BRONJ may appear 7 times more likely than medication used orally \[[@B41]\]. Ruggiero et. al \[[@B42]\] suggests that implant placement should be avoided in patients who are on intravenous bisphosphonate therapy or treated from cancer.

Results showed no significant implant success rate difference in intravenously and orally medicated groups, but only 3 case studies \[[@B31]\] with intravenous BPs were revised, which makes this study group statistically unreliable. On the other hand, intraoral BPs should be considered safe, assuming that only 5 out of 423 studied implants failed; although, Bell and Bell \[[@B37]\] mentioned that therapy of BPs did not seem to be a reason for the failed implants. American Association of Oral and Maxillofacial Surgeons \[[@B43]\], affirmed that using intraoral BPs more than 3 years gets patients to a higher risk of BRONJ appearance if oral surgical manipulations are done, although 3 cases studied patients with history of more than 3 years of intraoral drug consumption with high success of implantation procedures with only 5 implants failed out of 275 \[[@B35],[@B37],[@B38]\]. Treatment with implants can be considered safe with intraoral BPs; although, good preparation of patient pre-operatively (professional oral hygiene, drug holidays if needed, prescription of antibacterial mouth rinses) and proper time of medications (antibiotic therapy) and follow-ups (at least 12 months of re-evaluations) have to be done for success. However, dental implants on intravenously treated patients should be studied more and are considerably unreliable. On the other hand, there are a number of articles that offer successful BRONJ treatment combinations; some approaches could benefit primary wound closure on dental implant placement. For example, platelet-rich plasma showed high improvement of primary wound closure and healing factors in Bocanegra-Pérez et al. \[[@B44]\], and Curi et al. \[[@B45]\] presented cases, compared with patients treated without thrombocyte concentrates \[[@B46]\]. Even better improvement outcomes were seen with PRF (platelet-rich fibrin) with studies carried out by Dincă et al. \[[@B49]\] and Kim et al. \[[@B50]\] with significantly better recovery and less delayed healing signs. Studies carried out by Mozzati \[[@B51],[@B52]\] showed that treatment with PRGF (plasma rich in growth factors) showed the best after-effects with no complications or recurrences during the follow-up. Preventive and diagnostic strategies are important in avoiding implant-related BRONJ, according to Marx et al. \[[@B53]\] and Kunchur et al. \[[@B54]\], CTX values of 150 pg/mL and more greatly reduced the risk of osteonecrosis occurrence. Speaking on preventive strategies, Tardast et al. \[[@B55]\] also discovered that patients who already developed BRONJ and were on corticosteroid therapy had lower rates of healing than patients who didn't use corticosteroids. Post-operative care is important, as mentioned in an article published by Freiberger et al. \[[@B56]\] that indicated that hyperbaric oxygen therapies benefit patients with a higher tissue healing rate. In conclusion, planning of implantation procedures with good post- and pre-operative methods is as important as implantation protocol alone. Superior satisfying results could be achieved with more complex treatment methods.

CONCLUSIONS
===========

Few articles regarding patients treated with intravenous bisphosphonates and implant placement were found among the studied publications, meaning there is not enough evidence to ensure that implantation on these patients could be considered safe. Most of the studies investigated in this article showed high risk during the assessment of bias. More randomised trials with control groups are needed for statistically reliable results, meaning that precautions should be taken when assessing the final results.

Patients treated intravenously could have a higher chance of developing implant-related bisphosphonates-related osteonecrosis of the jaw. Intraoral bisphosphonates can be considered safe, if good pre- and post-operative care of the patient is in place. The mean age of medication taken for intraoral bisphosphonates does not seem to have any influence on the implant survival rate or the development of bisphosphonates-related osteonecrosis. Meanwhile, it is unreasonable to affirm that intravenous medication usage time can have an effect on implant-related bisphosphonates-related osteonecrosis due to the lack of patients and implants placed in the investigated group.
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